Drug Type Monoclonal antibody |
Synonyms EU 101, EU-101, NOV-1801 |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 31 May 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 31 May 2021 | |
Colorectal Cancer | Phase 2 | KR | 31 May 2021 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 31 May 2021 | |
Metastatic Renal Cell Carcinoma | Phase 2 | KR | 31 May 2021 | |
Prostatic Cancer | Phase 2 | US | 31 May 2021 | |
Prostatic Cancer | Phase 2 | KR | 31 May 2021 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 28 May 2021 | |
Neoplasms | Preclinical | CN | 01 Sep 2017 |